Act Wealth Management’s AIM ImmunoTech AIM Stock Holding History

Act Wealth Management’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-100	Closed	-$18K	–	36
2020 Q4	$18K	Buy	+100	New	+$20K	0.01%	30

Other funds holding AIM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Act Wealth Management's AIM Position: Q1 2021 in Review

Act Wealth Management sold out of AIM ImmunoTech (AIM) in Q1 2021, closing a stake of 100 shares — an estimated $18K sold.

Act Wealth Management first reported a position in AIM in Q4 2020 and held it in 1 quarter. The position peaked at $18K in Q4 2020. 35 funds tracked by Wall St. Rank hold AIM as of Q1 2021.

Act Wealth Management reported no remaining AIM ImmunoTech position as of Q1 2021 after selling out during the quarter.
Act Wealth Management sold 100 AIM ImmunoTech shares in Q1 2021, an estimated $18K.
Act Wealth Management first reported a position in AIM ImmunoTech in Q4 2020 and held it in 1 quarter.
Act Wealth Management's AIM ImmunoTech position peaked at $18K in Q4 2020.
35 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q1 2021.

Based on Act Wealth Management's 13F filing for Q1 2021, filed 8 Apr 2021.